FI971635L - Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi - Google Patents
Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi Download PDFInfo
- Publication number
- FI971635L FI971635L FI971635A FI971635A FI971635L FI 971635 L FI971635 L FI 971635L FI 971635 A FI971635 A FI 971635A FI 971635 A FI971635 A FI 971635A FI 971635 L FI971635 L FI 971635L
- Authority
- FI
- Finland
- Prior art keywords
- methods
- related conditions
- inhibiting neuropeptide
- neuropeptide
- inhibiting
- Prior art date
Links
- 101710151321 Melanostatin Proteins 0.000 title 1
- 102400000064 Neuropeptide Y Human genes 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Peptides Or Proteins (AREA)
- Detergent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/326,675 US6562862B1 (en) | 1994-10-20 | 1994-10-20 | Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y |
| PCT/US1995/013246 WO1996012490A1 (en) | 1994-10-20 | 1995-10-19 | Methods of inhibiting conditions associated with neuropeptide y |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI971635A7 FI971635A7 (fi) | 1997-04-17 |
| FI971635L true FI971635L (fi) | 1997-04-17 |
| FI971635A0 FI971635A0 (fi) | 1997-04-17 |
Family
ID=23273204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI971635A FI971635A0 (fi) | 1994-10-20 | 1995-10-19 | Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi |
Country Status (19)
| Country | Link |
|---|---|
| US (5) | US6562862B1 (fi) |
| EP (1) | EP0785785A4 (fi) |
| JP (1) | JPH10507757A (fi) |
| KR (1) | KR970706818A (fi) |
| CN (1) | CN1091598C (fi) |
| AU (1) | AU689664B2 (fi) |
| CA (1) | CA2200990A1 (fi) |
| CZ (1) | CZ287411B6 (fi) |
| FI (1) | FI971635A0 (fi) |
| HU (1) | HUT76852A (fi) |
| IL (1) | IL115663A (fi) |
| MY (1) | MY132056A (fi) |
| NO (1) | NO971520D0 (fi) |
| NZ (1) | NZ295575A (fi) |
| RU (1) | RU2188015C2 (fi) |
| TW (1) | TW410156B (fi) |
| UA (1) | UA46744C2 (fi) |
| WO (1) | WO1996012490A1 (fi) |
| ZA (1) | ZA958800B (fi) |
Families Citing this family (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5492927A (en) * | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5989920A (en) | 1994-12-02 | 1999-11-23 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior compounds useful in such methods and DNA encoding a hypothalmic atypical neuropeptide Y/peptide YY receptor Y5 |
| US5602024A (en) * | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| US5494929A (en) * | 1995-01-12 | 1996-02-27 | Eli Lilly And Company | Methods of inhibiting growth hormone effects |
| US5840747A (en) * | 1995-06-07 | 1998-11-24 | Eli Lilly And Company | Calcium channel antagonists |
| US5532254A (en) * | 1995-06-07 | 1996-07-02 | Eli Lilly And Company | Modulation of calcium channels using benzothiophenes |
| EP0759441A3 (en) * | 1995-06-30 | 1999-06-30 | Eli Lilly And Company | Methods of treating neuropeptide Y-associated conditions |
| WO1997026853A2 (en) * | 1996-01-24 | 1997-07-31 | Synaptic Pharmaceutical Corporation | Dna encoding galanin galr2 receptors and uses thereof |
| US5972624A (en) * | 1996-01-24 | 1999-10-26 | Synaptic Pharmaceutical Corporation | Method of identifying ligands which bind recombinant galanin receptor (GALR2) |
| US6113876A (en) * | 1996-01-29 | 2000-09-05 | Eli Lilly And Company | Methods of increasing sphincter competence |
| AU732473B2 (en) * | 1996-01-29 | 2001-04-26 | Eli Lilly And Company | Methods of increasing sphincter competence |
| EP0984778B1 (en) | 1996-08-23 | 2002-06-12 | Agouron Pharmaceuticals, Inc. | Neuropeptide-y ligands |
| US6329197B2 (en) | 1996-10-09 | 2001-12-11 | Synaptic Pharmaceutical Corporation | DNA encoding galanin GALR3 receptors and uses thereof |
| FR2754709B1 (fr) | 1996-10-23 | 1999-03-05 | Sanofi Sa | Composition cosmetique contenant un antagoniste des recepteurs du neuropeptide gamma et alpha 2 antagonistes susceptibles d'etre incorpores dans une telle composition |
| US5900418A (en) * | 1997-02-10 | 1999-05-04 | Synapse Pharmaceuticals International, Inc. | Method for treatment of obesity |
| US6048900A (en) | 1998-02-13 | 2000-04-11 | Bayer Corporation | Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists |
| WO1998035957A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| US6245817B1 (en) | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
| CA2251580A1 (en) * | 1997-02-14 | 1998-08-20 | Bayer Corporation | Amides as npy5 receptor antagonists |
| ZA982877B (en) * | 1997-04-09 | 1999-10-04 | Lilly Co Eli | Treatment of central nervous system disorders with selective estrogen receptor modulators. |
| WO1998047505A1 (en) * | 1997-04-23 | 1998-10-29 | Banyu Pharmaceutical Co., Ltd. | Neuropeptide y receptor antagonist |
| US6713265B1 (en) | 1997-06-04 | 2004-03-30 | Synaptic Pharmaceutical Corporation | Methods of modifying feeding behavior, compounds useful in such methods, and DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) |
| ATE234098T1 (de) * | 1997-08-05 | 2003-03-15 | Pfizer Prod Inc | 4-aminopyrrole (3,2-d) pyrimidinen als antagonisten des neuropeptide y receptors |
| US6187778B1 (en) | 1997-08-05 | 2001-02-13 | Pfizer Inc. | 4-aminopyrrole (3, 2-D) pyrimidines as neuropeptide Y receptor antagonists |
| US6008232A (en) * | 1997-08-20 | 1999-12-28 | Eli Lilly And Company | Methods for preventing headaches |
| AU9106198A (en) * | 1997-08-21 | 1999-03-08 | Eli Lilly And Company | Methods for inhibiting temporomandibular disorders |
| WO1999008523A1 (en) * | 1997-08-21 | 1999-02-25 | Eli Lilly And Company | Methods for inhibiting fibrous inflammatory disease and riedel's thyroiditis |
| US5990129A (en) * | 1997-09-23 | 1999-11-23 | Eli Lilly And Company | Methods for regulating trkA expression |
| US20050107327A1 (en) * | 1997-12-19 | 2005-05-19 | Hormos Medical Corporation | Method for reducing overproduction of neuropeptide Y in an individual |
| US6391922B1 (en) | 1998-01-13 | 2002-05-21 | Synchroneuron, Llc | Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders |
| US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
| GB2344050A (en) * | 1998-11-26 | 2000-05-31 | Ferring Bv | Agents useful in the treatment of reproductive disorders. |
| EP1027891B1 (en) * | 1999-01-27 | 2004-12-29 | Pfizer Products Inc. | Neuropeptide y antagonists |
| AU2512800A (en) * | 1999-02-03 | 2000-08-25 | Eli Lilly And Company | Alpha1-adrenergic receptor antagonists |
| DE19905961A1 (de) * | 1999-02-12 | 2000-08-17 | Stefan Neubauer | Verwendung von Östrogenen zur Behandlung der Herzinsuffizienz |
| AU3511500A (en) * | 1999-03-05 | 2000-09-21 | Trustees Of University Technology Corporation, The | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide-induced clinical conditions |
| AU2935200A (en) | 1999-04-30 | 2000-11-17 | Pfizer Products Inc. | Compounds for the treatment of obesity |
| ES2258476T3 (es) | 1999-09-30 | 2006-09-01 | Neurogen Corporation | Ciertos heterociclos sustituidos con alquilendiaminas. |
| WO2001026651A2 (en) * | 1999-10-14 | 2001-04-19 | Endorecherche, Inc. | Selective estrogen receptor modulators in the treatment or reduction of the risk of acquiring hypertension, cardiovascular diseases, and insulin resistance |
| US20040053864A1 (en) * | 2000-01-20 | 2004-03-18 | Gerard Karsenty | Methods and compositions for control of bone formation via modulation of neuropeptide y activity |
| JP2001261674A (ja) * | 2000-03-22 | 2001-09-26 | Mitsui Chemicals Inc | ベンゾチオフェン誘導体およびそれを有効成分として含有する核内レセプター作動薬 |
| US6511984B2 (en) | 2000-03-30 | 2003-01-28 | Pfizer Inc. | Neuropeptide Y antagonists |
| US20020061897A1 (en) | 2000-03-30 | 2002-05-23 | Elliott Richard L. | Neuropeptide Y antagonists |
| US6358991B2 (en) | 2000-07-06 | 2002-03-19 | American Home Products Corporation | Methods of treating neuropeptide Y-related conditions |
| TWI303990B (en) * | 2000-10-17 | 2008-12-11 | Pfizer Prod Inc | New use of estrogen agonists/antagonists for improving vascular health |
| AU2756602A (en) * | 2001-04-25 | 2002-10-31 | Pfizer Products Inc. | Methods and kits for treating depression or preventing deterioration of cognitive function |
| IL162269A0 (en) | 2001-12-05 | 2005-11-20 | Baylor College Medicine | Methods and compositions for control of bone formation via modulation of sympathetic tone |
| US6949564B2 (en) * | 2002-12-18 | 2005-09-27 | Pfizer Inc. | NPY-5 antagonists |
| US6958347B2 (en) * | 2002-12-18 | 2005-10-25 | Pfizer Inc. | Aminophenanthridinone and aminophenanthridine as NPY-5 antagonists |
| JP2004224756A (ja) * | 2003-01-24 | 2004-08-12 | Sumika Fine Chemicals Co Ltd | ２，６−ジハロゲノ−８−置換−プリン化合物およびその製造方法 |
| US20040220242A1 (en) * | 2003-05-02 | 2004-11-04 | Leland Shapiro | Inhibitors of serine protease activity, methods and compositions for treatment of nitric oxide induced clinical conditions |
| ATE462432T1 (de) | 2003-05-05 | 2010-04-15 | Probiodrug Ag | Glutaminylcyclase-hemmer |
| ES2228268B1 (es) * | 2003-07-30 | 2006-07-01 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6. |
| JP2007509898A (ja) | 2003-11-03 | 2007-04-19 | プロビオドルグ エージー | 神経障害治療に有用な組合せ |
| KR101099206B1 (ko) | 2004-02-05 | 2011-12-27 | 프로비오드룩 아게 | 신규한 글루타미닐 시클라제 저해제 |
| US8642079B2 (en) * | 2004-02-23 | 2014-02-04 | Hormos Medical Corporation | Solid formulations of ospemifene |
| US8758821B2 (en) * | 2004-05-04 | 2014-06-24 | Hormos Medical Ltd. | Oral formulations of ospemifene |
| CN1950071A (zh) * | 2004-05-04 | 2007-04-18 | 霍尔莫斯医疗有限公司 | ospemifene的新口服制剂 |
| EP1843819A2 (en) * | 2004-11-15 | 2007-10-17 | Obe Therapy Biotechnology S.A.S. | Methods of reducing body fat |
| AU2006235200A1 (en) * | 2005-04-15 | 2006-10-19 | Regenertech Pty Limited | Use of Neuropeptide Y (NPY) and agonists and antagonists thereof for tissue regeneration |
| JP5379692B2 (ja) | 2006-11-09 | 2013-12-25 | プロビオドルグ エージー | 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体 |
| EP2091948B1 (en) | 2006-11-30 | 2012-04-18 | Probiodrug AG | Novel inhibitors of glutaminyl cyclase |
| KR101510646B1 (ko) * | 2007-02-14 | 2015-04-10 | 호르모스 메디칼 리미티드 | 치료적으로 유용한 트리페닐부텐 유도체의 제조 방법 |
| WO2008099060A2 (en) * | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Methods for the preparation of fispemifene from ospemifene |
| CA2679446C (en) | 2007-03-01 | 2016-05-17 | Probiodrug Ag | New use of glutaminyl cyclase inhibitors |
| US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
| EP2225261B1 (en) | 2007-12-03 | 2016-03-09 | Obe Therapy Biotechnology | Boropeptide inhibitors of enteropeptidase and their uses in treatment of obesity, overweight and/or diseases associated with an abnormal fat metabolism |
| BR112012008346B1 (pt) | 2009-09-11 | 2021-12-21 | Vivoryon Therapeutics N.V. | Derivados heterocíclicos, seu processo de preparação, e composição farmacêutica |
| WO2011107530A2 (en) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Novel inhibitors |
| DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| WO2012123563A1 (en) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| EP2909164A1 (en) | 2012-10-19 | 2015-08-26 | Fermion Oy | A process for the preparation of ospemifene |
| EP2958907B1 (en) * | 2013-02-19 | 2018-02-28 | Novartis AG | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4133814A (en) | 1975-10-28 | 1979-01-09 | Eli Lilly And Company | 2-Phenyl-3-aroylbenzothiophenes useful as antifertility agents |
| US4380635A (en) | 1981-04-03 | 1983-04-19 | Eli Lilly And Company | Synthesis of acylated benzothiophenes |
| US4418068A (en) | 1981-04-03 | 1983-11-29 | Eli Lilly And Company | Antiestrogenic and antiandrugenic benzothiophenes |
| US4891357A (en) * | 1985-02-11 | 1990-01-02 | University Of Florida | Methods and compositions for stimulation of appetite |
| US5075321A (en) | 1987-03-24 | 1991-12-24 | University Of Pennsylvania | Methods of treating diseases characterized by interactions of IgG-containing immune complexes with macrophage Fc receptors using antiestrogenic benzothiophenes |
| SU1715354A1 (ru) * | 1988-05-04 | 1992-02-28 | Ставропольский государственный медицинский институт | Способ лечени депрессивных состо ний |
| SU1725899A1 (ru) * | 1990-02-20 | 1992-04-15 | Московский научно-исследовательский институт психиатрии | Способ лечени эндогенных депрессий |
| JP3157882B2 (ja) | 1991-11-15 | 2001-04-16 | 帝国臓器製薬株式会社 | 新規なベンゾチオフエン誘導体 |
| JPH07502268A (ja) | 1991-11-27 | 1995-03-09 | ノボ ノルディスク アクティーゼルスカブ | 化学化合物、それらの製法および使用 |
| TW366342B (en) | 1992-07-28 | 1999-08-11 | Lilly Co Eli | The use of 2-phenyl-3-aroylbenzothiophenes in inhibiting bone loss |
| TW383306B (en) | 1992-12-22 | 2000-03-01 | Lilly Co Eli | New use of 2-phenyl-3-aroylbenzothiophenes in lowering serum cholesterol |
| US5482949A (en) | 1993-03-19 | 1996-01-09 | Eli Lilly And Company | Sulfonate derivatives of 3-aroylbenzo[b]thiophenes |
| DE4311870C2 (de) | 1993-04-10 | 1998-07-30 | Altramed Holdings Ltd | Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen |
| US5445941A (en) | 1993-06-21 | 1995-08-29 | Eli Lilly And Company | Method for screening anti-osteoporosis agents |
| CZ285522B6 (cs) | 1993-06-24 | 1999-08-11 | Eli Lilly And Company | Farmaceutický prostředek pro snížení koncentrace glukosy v krvi |
| TW303299B (fi) | 1993-07-22 | 1997-04-21 | Lilly Co Eli | |
| US5468773A (en) | 1993-08-25 | 1995-11-21 | Eli Lilly And Company | Methods for inhibiting bone loss and cartilage degradation using wortmannin and its analogs |
| US5457113A (en) | 1993-10-15 | 1995-10-10 | Eli Lilly And Company | Methods for inhibiting vascular smooth muscle cell proliferation and restinosis |
| US6417198B1 (en) * | 1993-12-21 | 2002-07-09 | Eli Lilly And Company | Methods of inhibiting CNS problems in post-menopausal women |
| US5476862A (en) | 1993-12-21 | 1995-12-19 | Eli Lilly And Company | Methods of increasing thrombomodulin expression |
| US5439931A (en) | 1993-12-21 | 1995-08-08 | Eli Lilly And Company | Method for increasing libido in post-menopausal women |
| US5578613A (en) | 1993-12-21 | 1996-11-26 | Eli Lilly And Company | Methods for inhibiting weight gain or inducing weight loss |
| EP0659428A1 (en) | 1993-12-21 | 1995-06-28 | Eli Lilly And Company | 2-Phenyl-3-azoylbenzothiophenes for treating obsessive-compulsive and consumptive disorders |
| US5552415A (en) * | 1993-12-21 | 1996-09-03 | Eli Lilly And Company | Method of inhibiting Alzheimer's Disease |
| US5447941A (en) * | 1993-12-21 | 1995-09-05 | Eli Lilly And Company | Methods of inhibiting pulmonary hypertensive diseases with raloxifene and related benzothiophenes |
| US5574047A (en) | 1993-12-21 | 1996-11-12 | Eli Lilly And Company | Methods of inhibiting imperfect tissue repair |
| US5492927A (en) | 1993-12-21 | 1996-02-20 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists to treat allergy |
| US5441965A (en) | 1993-12-21 | 1995-08-15 | Eli Lilly And Company | Methods of inhibiting thrombin |
-
1994
- 1994-10-20 US US08/326,675 patent/US6562862B1/en not_active Expired - Fee Related
-
1995
- 1995-08-21 US US08/517,303 patent/US5504094A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,316 patent/US5576337A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,049 patent/US5567714A/en not_active Expired - Fee Related
- 1995-08-21 US US08/517,315 patent/US5567715A/en not_active Expired - Fee Related
- 1995-10-18 ZA ZA958800A patent/ZA958800B/xx unknown
- 1995-10-18 IL IL11566395A patent/IL115663A/xx not_active IP Right Cessation
- 1995-10-18 TW TW084110967A patent/TW410156B/zh not_active IP Right Cessation
- 1995-10-19 MY MYPI95003138A patent/MY132056A/en unknown
- 1995-10-19 UA UA97041869A patent/UA46744C2/uk unknown
- 1995-10-19 EP EP95938248A patent/EP0785785A4/en not_active Withdrawn
- 1995-10-19 KR KR1019970702591A patent/KR970706818A/ko not_active Ceased
- 1995-10-19 FI FI971635A patent/FI971635A0/fi unknown
- 1995-10-19 AU AU38955/95A patent/AU689664B2/en not_active Ceased
- 1995-10-19 RU RU97108050/14A patent/RU2188015C2/ru active
- 1995-10-19 JP JP8514008A patent/JPH10507757A/ja active Pending
- 1995-10-19 WO PCT/US1995/013246 patent/WO1996012490A1/en not_active Ceased
- 1995-10-19 CN CN95195703A patent/CN1091598C/zh not_active Expired - Fee Related
- 1995-10-19 CA CA002200990A patent/CA2200990A1/en not_active Abandoned
- 1995-10-19 HU HU9701520A patent/HUT76852A/hu unknown
- 1995-10-19 CZ CZ19971159A patent/CZ287411B6/cs not_active IP Right Cessation
-
1997
- 1997-04-03 NO NO971520A patent/NO971520D0/no not_active Application Discontinuation
- 1997-04-17 NZ NZ295575A patent/NZ295575A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0785785A4 (en) | 1998-11-11 |
| US6562862B1 (en) | 2003-05-13 |
| MY132056A (en) | 2007-09-28 |
| CN1091598C (zh) | 2002-10-02 |
| AU3895595A (en) | 1996-05-15 |
| NO971520L (no) | 1997-04-03 |
| ZA958800B (en) | 1997-04-18 |
| US5504094A (en) | 1996-04-02 |
| NO971520D0 (no) | 1997-04-03 |
| RU2188015C2 (ru) | 2002-08-27 |
| FI971635A7 (fi) | 1997-04-17 |
| EP0785785A1 (en) | 1997-07-30 |
| WO1996012490A1 (en) | 1996-05-02 |
| AU689664B2 (en) | 1998-04-02 |
| IL115663A (en) | 1999-08-17 |
| UA46744C2 (uk) | 2002-06-17 |
| US5576337A (en) | 1996-11-19 |
| US5567714A (en) | 1996-10-22 |
| JPH10507757A (ja) | 1998-07-28 |
| FI971635A0 (fi) | 1997-04-17 |
| IL115663A0 (en) | 1996-01-19 |
| HUT76852A (en) | 1997-12-29 |
| US5567715A (en) | 1996-10-22 |
| NZ295575A (en) | 2000-06-23 |
| TW410156B (en) | 2000-11-01 |
| CZ115997A3 (en) | 1997-10-15 |
| CA2200990A1 (en) | 1996-05-02 |
| KR970706818A (ko) | 1997-12-01 |
| MX9702853A (es) | 1997-07-31 |
| CN1160998A (zh) | 1997-10-01 |
| CZ287411B6 (en) | 2000-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI971635L (fi) | Menetelmät neuropeptidiin Y liittyvien tilojen inhiboimiseksi | |
| FI963597A7 (fi) | Isoprenyylitransferaasi-inhibiittoreita | |
| NO972930D0 (no) | Fibronectin-adhesjonsinhibitorer | |
| FI972160A0 (fi) | Matriisimetalloproteaasi-inhibiittorit | |
| DE69724809D1 (de) | Refluxinhibitoren | |
| FI962904A7 (fi) | Metalloproteinaasi-inhibiittoreita | |
| FI962905A7 (fi) | Metalloproteinaasi-inhibiittoreita | |
| BR9509610A (pt) | Ligandos específicos de neuropeptideo Y1 | |
| FI950800L (fi) | Menetelmä heterosyklisten yhdisteiden sulfinyloimiseksi | |
| FI962749L (fi) | Uusia heterosyklisiä yhdisteitä | |
| NO991563D0 (no) | N-substituerte azaheterosykliske forbindelser | |
| FI972198L (fi) | Metalloproteinaasi-inhibiittoreita | |
| BR9509015A (pt) | Inibidores de 5alfa-reductase | |
| NO991564D0 (no) | N-substituerte azaheterosykliske forbindelser | |
| BR9503042A (pt) | Composto de polialquilpiperidina | |
| FI971675L (fi) | Menetelmä bradykiniinin liittyvien tilojen inhiboimiseksi | |
| NO972607D0 (no) | Sekvestreringsmidler | |
| FI941265A7 (fi) | Heterosyklisiä sulfoniamidotrombiini-inhibiittoreita | |
| CY2007006I2 (el) | Αναστολεις συνθεσεις απολιποπρωτεϊνης-β | |
| SE9400968D0 (sv) | Heterocyclic compounds | |
| SE9402122D0 (sv) | Heterocyclic compounds | |
| KR960014785U (ko) | 오일 유입 방지용 니폴 | |
| ATE228999T1 (de) | Metalloproteinaseinhibitoren | |
| FI965153A7 (fi) | Metalloproteinaasi-inhibiittorit |